Navigation Links
Trillium and Biogen Idec enter into global license agreement
Date:1/12/2010

biopharmaceutical company specializing in innovative therapies of immune-mediated conditions, such as autoimmune and inflammatory disorders, as well as cancer. The company's lead program, TTI-1612, is a recombinant growth factor that is being developed for the treatment of interstitial cystitis (IC) and the prevention of necrotizing enterocolitis (NEC). Trillium has broad portfolio preclinical immunology programs, including two that target the CD200 immunoregulatory axis; a CD200-specific monoclonal antibody for the treatment of cancer, and a CD200Fc fusion protein for the treatment of autoimmune and inflammatory diseases. In addition, the company has an FcyRlla-specific humanized monoclonal antibody in development for treatment of immune complex-mediated inflammatory diseases.

The company has a broad network of external academic and industry R&D collaborations, including several license agreements with major US biotechnology companies. The Company is supported by three premier venture capital investors: Vengrowth Private Equity Partners, Growthworks Capital and BDC Capital.

SOURCE Trillium Therapeutics Inc.


'/>"/>
SOURCE Trillium Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
2. Trillium Strengthens its Board of Directors
3. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
4. Biogenerics Will Save Billions, Says Hospira CEO
5. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
6. Icahn Confirms Intention to Nominate Three Directors at Biogen
7. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
8. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
9. CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years
10. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
11. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... September 16, 2014 Pharma ... to position themselves for their 89th year ... and encoding, Pharma Packaging Solutions is preparing ... and software and new procedures. Establishing training ... Manufacturing Practices (cGMP), Pharma Packaging Solutions will ...
(Date:9/16/2014)... Sept. 16, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... The full interim results will be presented at ... IGF Society, being held October 15-18, 2014, in ...
(Date:9/16/2014)... Australia (PRWEB) September 16, 2014 RENU 28, ... Signaling molecules, became available for purchase in Australia and ... a nationwide tour beginning September 16th. The tour will make ... the 17th, Bundaberg on the 18th, Sydney on the 20th, ... market in Australia and New Zealand and to educate people ...
(Date:9/15/2014)... , Sept. 15, 2014 EnGeneIC, ... revolutionizing the treatment of cancer through the targeted ... announced that, together with the Asbestos Disease Research ... Institute New South Wales (NSW) Premier,s Award for ... recipients are the hospitals that will be involved ...
Breaking Biology Technology:Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Wellness Company Hosts ASEA Australia Tour September 16-22 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3
... DENVER, Nov. 18, 2010 BioSpace ... Campaign this morning, showcasing biotechnological, pharmaceutical ... States and Canada. (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO) ... campaign promotes life science organizations within Oregon, ...
... Inc. (OTCBB: GNLK ), a leading consumer genomics biotech company, today ... Highlights: Gross Profit Margin ... for the second year in a row GeneLink announces Private ... GeneLink,s CEO stated, "The third quarter of 2010 continues to reflect ...
... Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are ...
Cached Biology Technology:BioSpace Highlights the Northwest's Growing Life Science Region 2GeneLink Reports Third Quarter Results 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 2Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 3Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 4Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 5Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 6Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 7Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 8Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 9Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 10Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany 11
(Date:9/16/2014)... votes for independence later this week, its Government could ... that fracking is necessary, research has revealed. , The ... public perception of shale gas extraction in the UK ... north of the border are the least supportive of ... in the University,s School of Geography, said: "The clear ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... million gallons of oil into Alaska,s Prince William Sound. ... in the Gulf of Mexico in 2010. According to ... Research , news coverage of environmental disasters serves to ... the way fossil fuels are used. , "We found ... events helped to resolve many of the cultural anxieties ...
Breaking Biology News(10 mins):Scottish people most sceptical on fracking, survey shows 2Scottish people most sceptical on fracking, survey shows 3Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2
... a mission to sniff out trouble and display their ... of Naval Research (ONR)-hosted "Top Dog Demo 2012." ... move through the battle space," said Lisa Albuquerque, program ... ONR,s Expeditionary Warfare and Combating Terrorism department. "Marines can ...
... high speed rail lines in China will be the topic ... Liu takes the stage at the annual 91st Transportation Research ... gathering in transportation, if not all of engineering, with upwards ... an expert in high speed rail lines and other transportation ...
... EAST LANSING, Mich. -- A receptor found on blood platelets ... questioned may in fact be fruitful in drug testing, according ... team led by Dana Spence of MSU,s Department of Chemistry ... known as P2X1. By creating a new, simple method to ...
Cached Biology News:Marine's best friend shows explosive-detecting capabilities 2NJIT high speed rail expert to address DC conference next week 2NJIT high speed rail expert to address DC conference next week 3Chemists unlock potential target for drug development 2
Presenilin-1, N-terminus....
Request Info...
Human DEP-1/CD148 Fluorescein MAb (Clone 143-41) Protein Family: Granulocyte Markers, Monocyte Markers, Phosphatases & Regulators, Other Dendritic Cell Molecules...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: